PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hołubowicz, R.* ; Gao, F.* ; Du, S.W.* ; Menezes, C.R.* ; Zhang, J.* ; Hołubowicz, M.W.* ; Chen, P.Z.* ; Armbrust, N. ; Geilenkeuser, J. ; Liu, D.R.* ; Truong, D.J.J. ; Westmeyer, G.G. ; Palczewska, G.* ; Palczewski, K.*

Scalable purification enables high-quality virus-like particles for therapeutic translation.

J. Biol. Chem., DOI: 10.1016/j.jbc.2025.110946:110946 (2025)
Postprint DOI PMC
Open Access Green
Emerging molecular therapies introduce enzymatic activity into cells by delivering genes, transcripts, or proteins. Owing to their robust cell-entry capacity, virus-like particles (VLPs) represent a technology of choice in genome editing, where low doses of heterologous proteins and nucleic acids are essential. However, clinical translation of VLP vectors is hindered by inadequate purification methods. Current approaches, relying primarily on ultracentrifugation, suffer from inconsistent product quality and poor scalability. Here, we report the development of a broadly applicable purification strategy that improves the purity and therapeutic efficacy of genome-editing VLPs. Considering the characteristic properties of murine leukemia virus (MLV)-derived engineered VLPs (eVLPs) and HIV-derived engineered nucleocytosolic vehicles for loading of programmable editors (ENVLPEs+), we developed a workflow that involves single- and multi-modal chromatographic steps, effectively removing host cell proteins and cell-culture contaminants while improving VLP integrity and biological activity. Our purified VLPs displayed superior protein composition, consistency, and enhanced functional delivery compared to VLPs partially purified by conventional ultracentrifugation methods. Mass spectrometric analysis revealed a substantial decrease in contaminants, with VLP-specific proteins comprising >90% of the final product. In vivo studies confirmed improved therapeutic outcomes when chromatographically purified VLPs were used. Our scalable purification platform addresses critical manufacturing bottlenecks and constitutes a starting point for further development of VLP therapeutics, enabling robust production of pure VLPs for diverse applications such as genome editing, vaccine development, and other uses that require intracellular protein delivery.
Impact Factor
Scopus SNIP
Altmetric
3.900
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Crispr/cas ; Cas9 ; Base Editing ; Chromatography ; Nanotechnology ; Prime Editing ; Protein Delivery ; Ribonuclear Protein (rnp) ; Vesicles ; Virus-like Particles
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0021-9258
e-ISSN 1083-351X
Zeitschrift Journal of Biological Chemistry, The
Quellenangaben Band: , Heft: , Seiten: , Artikelnummer: 110946 Supplement: ,
Verlag American Society for Biochemistry and Molecular Biology
Begutachtungsstatus Peer reviewed
Institut(e) Insitute of Synthetic Biomedicine (ISBM)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-509300-001
DOI 10.1016/j.jbc.2025.110946
PubMed ID 41241097
Erfassungsdatum 2025-11-19
[➜Korrektur melden]